Cargando…

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia

The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease which binds to the low-density lipoprotein (LDL) receptors and targets the receptors for lysosomal degradation, offered an additional route through which plasma LDL-cholesterol (LDL-C) levels can be controlled....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosmas, Constantine E., Muñoz Estrella, Alba, Sourlas, Andreas, Silverio, Delia, Hilario, Elizabeth, Montan, Peter D., Guzman, Eliscer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163360/ https://www.ncbi.nlm.nih.gov/pubmed/30011788 http://dx.doi.org/10.3390/diseases6030063

Ejemplares similares

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2019)

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Primary genetic disorders affecting high density lipoprotein (HDL)
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Therapeutic management of hyperlipoproteinemia (a)
por: Kosmas, Constantine E, et al.
Publicado: (2019)

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2022)

The Impact of Insulin Resistance and Chronic Kidney Disease on Inflammation and Cardiovascular Disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

New and emerging lipid-modifying drugs to lower LDL cholesterol
por: Kosmas, Constantine E, et al.
Publicado: (2021)

Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary
por: Vohra, Laiba Imran, et al.
Publicado: (2023)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
por: Kosmas, Constantine E, et al.
Publicado: (2017)

Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia
por: Ebenezer, Oluwakemi, et al.
Publicado: (2023)

Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Correction to: Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Can Clinicians Start Prescribing Inclisiran for Hypercholesterolemia Today? A Review of Clinical Studies for Internal Medicine Physicians and Endocrinologists
por: Jahangir, Abdullah, et al.
Publicado: (2021)

Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
por: Kosmas, Constantine E., et al.
Publicado: (2023)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

Inclisiran: a novel drug for the treatment of dyslipidemia
por: Nadeem, Abdullah, et al.
Publicado: (2023)

New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Inclisiran: How Widely and When Should We Use It?
por: Pirillo, Angela, et al.
Publicado: (2022)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Inclisiran: a new generation of lipid-lowering siRNA therapeutic
por: Zhang, Yanzhen, et al.
Publicado: (2023)

Insulin resistance and cardiovascular disease
por: Kosmas, Constantine E., et al.
Publicado: (2023)

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report
por: Allevi, Massimiliano, et al.
Publicado: (2023)

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
por: Ray, Kausik K, et al.
Publicado: (2022)

Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews
por: Li, Jiayi, et al.
Publicado: (2023)

Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
por: Dec, Adrianna, et al.
Publicado: (2023)

The promising novel therapies for familial hypercholesterolemia
por: Chen, Ruoyu, et al.
Publicado: (2022)

Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials
por: Cupido, Arjen J, et al.
Publicado: (2020)

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

Lipid lowering with inclisiran: a real-world single-centre experience
por: Padam, Pritpal, et al.
Publicado: (2022)

The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran
por: Elserafy, Ahmed Shawky, et al.
Publicado: (2022)

Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
por: Rakocevic, Jelena, et al.
Publicado: (2023)

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
por: Albosta, Michael S, et al.
Publicado: (2023)

The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease
por: Kosmas, Constantine E., et al.
Publicado: (2023)

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
por: Ray, Kausik K, et al.
Publicado: (2022)

Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
por: Nishikido, Toshiyuki
Publicado: (2023)

The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lfbluogfh0oa6dmu3g78r319k4